Kidney Week

Oral Abstract Session

High-Impact Clinical Trials - 2

November 08, 2025 | 10:30 AM - 12:30 PM

Location: Hall A, Convention Center

Session Description

High-Impact Clinical Trials, Part 2

Note: Continuing education credits are not being offered for this session.

Learning Pathway(s)

• Other

Moderators

• Laura M. Dember, MD, FASN
• Richard Haynes, MBChB

Presentations

• Safety and Preliminary Efficacy Findings from a Phase 2A Randomized, Double-Blind, Placebo-Controlled Trial of Setanaxib in Patients with Alport Syndrome
  10:30 AM - 10:45 AM
  
  • Daniel P. Gale, MA, MBChB, PhD

Safety and Preliminary Efficacy Findings from a Phase 2A Randomized, Double-Blind, Placebo-Controlled Trial of Setanaxib in Patients with Alport Syndrome

November 08, 2025 | 10:30 AM - 10:45 AM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Efficacy and Safety of Telitacicept in Patients with IgAN: Results from Stage A of a Phase 3 Clinical Study
  10:45 AM - 11:00 AM
  
  • Jicheng Lv

Efficacy and Safety of Telitacicept in Patients with IgAN: Results from Stage A of a Phase 3 Clinical Study

November 08, 2025 | 10:45 AM - 11:00 AM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Beyond Clinical Response in the REGENCY Trial: The Impact of Obinutuzumab on Histologic Remission in Patients with Active Lupus Nephritis
  11:00 AM - 11:15 AM
  
  • Brad Rovin, FASN

Beyond Clinical Response in the REGENCY Trial: The Impact of Obinutuzumab on Histologic Remission in Patients with Active Lupus Nephritis

November 08, 2025 | 11:00 AM - 11:15 AM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Efficacy and Safety of MIL62, a Glycoengineered Type II Anti-CD20 Antibody, in Primary Membranous Nephropathy: A Phase 3, Randomized, Controlled Trial
  11:15 AM - 11:30 AM
  
  • Zhao Cui, MD

Efficacy and Safety of MIL62, a Glycoengineered Type II Anti-CD20 Antibody, in Primary Membranous Nephropathy: A Phase 3, Randomized, Controlled Trial

November 08, 2025 | 11:15 AM - 11:30 AM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Sibeprenlimab for the Treatment of IgAN: VISIONARY Phase 3 Interim and Prespecified Subgroup Analyses
  11:30 AM - 11:45 AM
  
  • Vlado Perkovic, MBBS, PhD, FASN

Sibeprenlimab for the Treatment of IgAN: VISIONARY Phase 3 Interim and Prespecified Subgroup Analyses

November 08, 2025 | 11:30 AM - 11:45 AM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Efficacy and Safety of Balcinrenone in Combination with Dapagliflozin on Albuminuria in Participants with CKD
  11:45 AM - 12:00 PM
  
  • Hiddo Jan L. Heerspink, PhD

Efficacy and Safety of Balcinrenone in Combination with Dapagliflozin on Albuminuria in Participants with CKD

November 08, 2025 | 11:45 AM - 12:00 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.